U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs ...

President Trump has announced a new agreement with nine major drug companies to lower drug prices in the U.S., promising ...

President Trump announced landmark drug pricing agreements with nine pharmaceutical companies and the launch of TrumpRx.gov, ...

The companies agreed to sell most of their drugs to Medicaid at the prices they charge in European countries and to sell ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug pricing deals.

In his latest effort to lower drug costs, President Donald Trump unveiled Friday “Most Favored Nation” pricing deals with nine more pharmaceutical companies.

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash ...

Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, ...

Merck (MRK) stock is a buy as Q3 beats estimates, driven by Keytruda, pipeline growth, and strong technicals. Read here for more analysis.